References
- Singh SRK, et al. NCDB analysis of melanoma 2004-2015: Epidemiology and outcomes by subtype, sociodemographic factors impacting clinical presentation, and real-world survival benefit of immunotherapy approval. Cancers (Basel). 2021;13(6):1455. DOI:https://doi.org/10.3390/cancers13061455
- Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (checkmate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–1492. DOI:https://doi.org/10.1016/S1470-2045(18)30700-9.
- Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. DOI:https://doi.org/10.1093/annonc/mdz011.
- Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. DOI:https://doi.org/10.1016/S0140-6736(17)31601-X.
- Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta. 2009;1796(2):176–193.
- Russano M, Napolitano A, Ribelli G, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020;39(1):95. DOI:https://doi.org/10.1186/s13046-020-01601-2.
- Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol. 2018;10:1758835918794630.
- Ferracin M, Lupini L, Salamon I, et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget. 2015;6(16):14545–14555. DOI:https://doi.org/10.18632/oncotarget.3859.
- Riefolo M, Porcellini E, Dika E, et al. Interplay between small and long non-coding RNA s in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Mol Oncol. 2019;13(1):74–98. DOI:https://doi.org/10.1002/1878-0261.12412.
- Volinia S, Calin GA, Liu C-G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–2261. DOI:https://doi.org/10.1073/pnas.0510565103.
- Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9(2):276. DOI:https://doi.org/10.3390/cells9020276.
- Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854.
- Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006;13(12):1097–1101.
- Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–4060. DOI:https://doi.org/10.1038/sj.emboj.7600385.
- Lee Y, Ahn C, Han J, et al. The nuclear RNase III drosha initiates microRNA processing. Nature. 2003;425(6956):415–419. DOI:https://doi.org/10.1038/nature01957.
- Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the dicer complex to ago2 for microRNA processing and gene silencing. Nature. 2005;436(7051):740–744. DOI:https://doi.org/10.1038/nature03868.
- Zhang H, et al. Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J. 2002;21(21):5875–5885. DOI:https://doi.org/10.1093/emboj/cdf582.
- Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–5008. DOI:https://doi.org/10.1073/pnas.1019055108.
- Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. DOI:https://doi.org/10.1038/cr.2008.282.
- Chim SS, Shing TKF, Hung ECW, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008;54(3):482–490. DOI:https://doi.org/10.1373/clinchem.2007.097972.
- Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–1741. DOI:https://doi.org/10.1373/clinchem.2010.147405.
- Cui M, et al. Circulating microRNAs in cancer: Potential and challenge. Front Genet. 2019;10:626.
- Cocks A, et al. Diverse roles of EV-RNA in cancer progression. Semin Cancer Biol. 2021;75:127–135.
- Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. DOI:https://doi.org/10.1080/20013078.2018.1535750.
- Falcone G, Felsani A, D’Agnano I. Signaling by exosomal microRNAs in cancer. J Exp Clin Cancer Res. 2015;34:32.
- Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015;13(1):17–24. DOI:https://doi.org/10.1016/j.gpb.2015.02.001.
- Mills J, Capece M, Cocucci E, et al. Cancer-derived extracellular vesicle-associated microRNAs in intercellular communication: one cell’s trash is another cell’s treasure. Int J Mol Sci. 2019;20(24):6109. DOI:https://doi.org/10.3390/ijms20246109.
- Groot M, Lee H. Sorting mechanisms for microRNAs into extracellular vesicles and their associated diseases. Cells. 2020;9(4):1044.
- Geekiyanage H, Rayatpisheh S, Wohlschlegel JA, et al. Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides. Proc Natl Acad Sci U S A. 2020;117(39):24213–24223. DOI:https://doi.org/10.1073/pnas.2008323117.
- Yao B, La LB, Chen Y-C, et al. Defining a new role of GW182 in maintaining miRNA stability. EMBO Rep. 2012;13(12):1102–1108. DOI:https://doi.org/10.1038/embor.2012.160.
- Maggi LB Jr., Kuchenruether M, Dadey DYA, et al. Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol. 2008;28(23):7050–7065. DOI:https://doi.org/10.1128/MCB.01548-07.
- Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol. 2012;9(8):1066–1075.
- Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–7233. DOI:https://doi.org/10.1093/nar/gkr254.
- Vickers KC, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–433. DOI:https://doi.org/10.1038/ncb2210.
- Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. DOI:https://doi.org/10.1038/ncb1596.
- Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–1476. DOI:https://doi.org/10.1038/ncb1800.
- Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285(23):17442–17452. DOI:https://doi.org/10.1074/jbc.M110.107821.
- Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011;2:282.
- Kogure T, Lin W-L, Yan IK, et al. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011;54(4):1237–1248. DOI:https://doi.org/10.1002/hep.24504.
- Makarova JA, Shkurnikov MU, Wicklein D, et al. Intracellular and extracellular microRNA: An update on localization and biological role. Prog Histochem Cytochem. 2016;51(3–4):33–49. DOI:https://doi.org/10.1016/j.proghi.2016.06.001.
- O’Brien K, Breyne K, Ughetto S, et al. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21(10):585–606. DOI:https://doi.org/10.1038/s41580-020-0251-y.
- Zhang Q, Higginbotham JN, Jeppesen DK, et al. Transfer of functional cargo in exomeres. Cell Rep. 2019;27(3):940–954 e6. DOI:https://doi.org/10.1016/j.celrep.2019.01.009.
- Yang Q, Diamond MP, Al-Hendy A. The emerging role of extracellular vesicle-derived miRNAs: implication in cancer progression and stem cell related diseases. J Clin Epigenet. 2016;2(1.
- Wu H, Zhou J, Mei S, et al. Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med. 2017;21(6):1228–1236. DOI:https://doi.org/10.1111/jcmm.13056.
- Fong MY, Zhou W, Liu L, et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 2015;17(2):183–194. DOI:https://doi.org/10.1038/ncb3094.
- Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011;71(15):5346–5356. DOI:https://doi.org/10.1158/0008-5472.CAN-11-0241.
- Mao L, Li J, Chen W-X, et al. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumour Biol. 2016;37(4):5247–5256. DOI:https://doi.org/10.1007/s13277-015-4402-2.
- Fernandez-Messina L, Gutiérrez-Vázquez C, Rivas-García E, et al. Immunomodulatory role of microRNAs transferred by extracellular vesicles. Biol Cell. 2015;107(3):61–77. DOI:https://doi.org/10.1111/boc.201400081.
- Yang M, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Vol. 10, Mol Cancer; 2011. 117.
- Del Vecchio F, Martinez‐Rodriguez V, Schukking M, et al. Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T-cells and tumour cells. J Extracell Vesicles. 2021;10(6):e12075. DOI:https://doi.org/10.1002/jev2.12075.
- Zhu L, Kalimuthu S, Gangadaran P, et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics. 2017;7(10):2732–2745. DOI:https://doi.org/10.7150/thno.18752.
- Yin Y, Cai X, Chen X, et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014;24(10):1164–1180. DOI:https://doi.org/10.1038/cr.2014.121.
- Ding G, Zhou L, Qian Y, et al. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 2015;6(30):29877–29888. DOI:https://doi.org/10.18632/oncotarget.4924.
- Zhou M, Chen J, Zhou L, et al. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Cell Immunol. 2014;292(1–2):65–69. DOI:https://doi.org/10.1016/j.cellimm.2014.09.004.
- Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012;109(31):E2110–6. DOI:https://doi.org/10.1073/pnas.1209414109.
- Miotto E, Saccenti E, Lupini L, et al. Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2638–2642. DOI:https://doi.org/10.1158/1055-9965.EPI-14-0503.
- Binderup HG, Madsen JS, Heegaard NHH, et al. Quantification of microRNA levels in plasma impact of preanalytical and analytical conditions. PLoS One. 2018;13(7):e0201069. DOI:https://doi.org/10.1371/journal.pone.0201069.
- Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn. 2013;15(6):827–834.
- Tiberio P, Callari M, Angeloni V, et al. Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 2015;2015:731479.
- Moldovan L, Batte KE, Trgovcich J, et al. Methodological challenges in utilizing mi RNA s as circulating biomarkers. J Cell Mol Med. 2014;18(3):371–390. DOI:https://doi.org/10.1111/jcmm.12236.
- Mompeon A, Ortega-Paz L, Vidal-Gómez X, et al. Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis. Sci Rep. 2020;10(1):5373. DOI:https://doi.org/10.1038/s41598-020-61507-z.
- Kannan M, Atreya C. Differential profiling of human red blood cells during storage for 52 selected microRNAs. Transfusion. 2010;50(7):1581–1588.
- Sidstedt M, Hedman J, Romsos EL, et al. Inhibition mechanisms of hemoglobin, immunoglobulin G, and whole blood in digital and real-time PCR. Anal Bioanal Chem. 2018;410(10):2569–2583. DOI:https://doi.org/10.1007/s00216-018-0931-z.
- Moret I, Sánchez-Izquierdo D, Iborra M, et al. Assessing an improved protocol for plasma microRNA extraction. PLoS One. 2013;8(12):e82753. DOI:https://doi.org/10.1371/journal.pone.0082753.
- Coenen-Stass AML, Magen I, Brooks T, et al. Evaluation of methodologies for microRNA biomarker detection by next generation sequencing. RNA Biol. 2018;15(8):1133–1145. DOI:https://doi.org/10.1080/15476286.2018.1514236.
- Wong RKY, MacMahon M, Woodside JV, et al. A comparison of RNA extraction and sequencing protocols for detection of small RNAs in plasma. BMC Genomics. 2019;20(1):446. DOI:https://doi.org/10.1186/s12864-019-5826-7.
- Hardikar AA, Farr RJ, Joglekar MV. Circulating microRNAs: understanding the limits for quantitative measurement by real-time PCR. J Am Heart Assoc. 2014;3(1):e000792.
- Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013;10(10):1003–1005. DOI:https://doi.org/10.1038/nmeth.2633.
- Dingle TC, Sedlak RH, Cook L, et al. Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances. Clin Chem. 2013;59(11):1670–1672. DOI:https://doi.org/10.1373/clinchem.2013.211045.
- Apalla Z, Lallas A, Sotiriou E, et al. Epidemiological trends in skin cancer. Dermatol Pract Concept. 2017;7(2):1–6. DOI:https://doi.org/10.5826/dpc.0702a01.
- Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: From pathogenesis to therapy (review). Int J Oncol. 2018;52(4):1071–1080. DOI:https://doi.org/10.3892/ijo.2018.4287.
- Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83(8):1664–1678. The American College of Surgeons Commission on Cancer and the American Cancer Society. DOI:https://doi.org/10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G.
- Dika E, Patrizi A, Fanti PA, et al. The prognosis of nail apparatus melanoma: 20 years of experience from a single institute. Dermatology. 2016;232(2):177–184. DOI:https://doi.org/10.1159/000441293.
- Ocanha-Xavier JP, Xavier-Junior JCC, Marques MEA. Melanoma: clinical, evolutive and histopathological characteristics of a series of 136 cases. An Bras Dermatol. 2018;93(3):373–376.
- Herschorn A. Dermoscopy for melanoma detection in family practice. Can Fam Physician. 2012;58(7):740–5, e372-8.
- Marghoob NG, Liopyris K, Jaimes N. Dermoscopy: A review of the structures that facilitate melanoma detection. J Am Osteopath Assoc. 2019;119(6):380–390.
- Hartman RI, Lin JY. Cutaneous melanoma-a review in detection, staging, and management. Hematol Oncol Clin North Am. 2019;33(1):25–38.
- Strojan P. Role of radiotherapy in melanoma management. Radiol Oncol. 2010;44(1):1–12.
- Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.
- Hamid O, et al. Efficacy, safety, and tolerability of approved combination braf and mek inhibitor regimens for braf-mutant melanoma. Cancers (Basel). 2019;11(11):1642. DOI:https://doi.org/10.3390/cancers11111642.
- Dika E, Ravaioli GM, Fanti PA, et al. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study. Eur J Dermatol. 2017;27(3):266–270. DOI:https://doi.org/10.1684/ejd.2017.3023.
- Leidinger P, Keller A, Borries A, et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer. 2010;10:262.
- Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010;15(7):673–682. DOI:https://doi.org/10.1634/theoncologist.2010-0103.
- Saldanha G, Potter L, Shendge P, et al. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma. J Invest Dermatol. 2013;133(5):1381–1384. DOI:https://doi.org/10.1038/jid.2012.477.
- Ichigozaki Y, Fukushima S, Jinnin M, et al. Serum long non-coding RNA, snoRNA host gene 5 level as a new tumor marker of malignant melanoma. Exp Dermatol. 2016;25(1):67–69. DOI:https://doi.org/10.1111/exd.12868.
- Fogli S, Polini B, Carpi S, et al. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol. 2017;39(5):1010428317701646. DOI:https://doi.org/10.1177/1010428317701646.
- Armand-Labit V, Meyer N, Casanova A, et al. Identification of a circulating microRNA profile as a biomarker of metastatic cutaneous melanoma. Acta Derm Venereol. 2016;96(1):29–34. DOI:https://doi.org/10.2340/00015555-2156.
- Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br J Cancer. 2018;118(6):857–866.
- Kanemaru H, Fukushima S, Yamashita J, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61(3):187–193. DOI:https://doi.org/10.1016/j.jdermsci.2010.12.010.
- Li P, et al. Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma. Med Sci Monit. 2014;20:2472–2477.
- Greenberg E, Besser MJ, Ben-Ami E, et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013;18(6):502–508. DOI:https://doi.org/10.3109/1354750X.2013.816777.
- Tian R, Liu T, Qiao L, et al. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. Int J Clin Exp Pathol. 2015;8(3):3097–3103.
- Margue C, Reinsbach S, Philippidou D, et al. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget. 2015;6(14):12110–12127. DOI:https://doi.org/10.18632/oncotarget.3661.
- Stark MS, Klein K, Weide B, et al. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: A microRNA expression analysis. EBioMedicine. 2015;2(7):671–680. DOI:https://doi.org/10.1016/j.ebiom.2015.05.011.
- Guo S, Guo W, Li S, et al. Serum miR-16: A potential biomarker for predicting melanoma prognosis. J Invest Dermatol. 2016;136(5):985–993. DOI:https://doi.org/10.1016/j.jid.2015.12.041.
- Pfeffer SR, Grossmann K, Cassidy P, et al. Detection of exosomal miRNAs in the plasma of melanoma patients. J Clin Med. 2015;4(12):2012–2027. DOI:https://doi.org/10.3390/jcm4121957.
- Alegre E, Sanmamed MF, Rodriguez C, et al. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med. 2014;138(6):828–832. DOI:https://doi.org/10.5858/arpa.2013-0134-OA.
- Tengda L, Shuping L, Mingli G, et al. Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res. 2018;28(4):295–303. DOI:https://doi.org/10.1097/CMR.0000000000000450.
- Friedman EB, Shang S, de Miera EV-S, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med. 2012;10:155.
- Shiiyama R, Fukushima S, Jinnin M, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013;23(5):366–372. DOI:https://doi.org/10.1097/CMR.0b013e328363e485.
- Fleming NH, Zhong J, da Silva IP, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients: Prognostic serum miRNAs in melanoma. Cancer. 2015;121(1):51–59. DOI:https://doi.org/10.1002/cncr.28981.
- Bai M, Zhang H, Si L, et al. Upregulation of serum miR-10b is associated with poor prognosis in patients with melanoma. J Cancer. 2017;8(13):2487–2491. DOI:https://doi.org/10.7150/jca.18824.
- Ono S, Oyama T, Lam S, et al. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015;6(9):7053–7064. DOI:https://doi.org/10.18632/oncotarget.3142.
- Gao X, Sui H, Zhao S, et al. Immunotherapy targeting myeloid-derived suppressor cells (MDSCs) in tumor microenvironment. Front Immunol. 2021;11:585214.
- Huber V, Vallacchi V, Fleming V, et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J Clin Invest. 2018;128(12):5505–5516. DOI:https://doi.org/10.1172/JCI98060.
- Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: A review of high-risk and metastatic disease. Am J Clin Dermatol. 2016;17(5):491–508.
- Sgouros D, Theofili M, Damaskou V, et al. Dermoscopy as a tool in differentiating cutaneous squamous cell carcinoma from its variants. Dermatol Pract Concept. 2021;11(2):e2021050. DOI:https://doi.org/10.5826/dpc.1102a50.
- Cinotti E, Tognetti L, Cartocci A, et al. Line-field confocal optical coherence tomography for actinic keratosis and squamous cell carcinoma: a descriptive study. Clin Exp Dermatol. 2021;46:1530–1541.
- Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237–247.
- Zhao Z, Wu Y, Zhou Z, et al. ALA-PDT successfully treated multiple cSCC in situ and AK in a patient with epidermodysplasia verruciformis. Photodiagnosis Photodyn Ther. 2021;35:102395.
- Koukourakis IM, Giakzidis AG, Kouroupi M, et al. Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. BJR Case Rep. 2021;7(3):20200170. DOI:https://doi.org/10.1259/bjrcr.20200170.
- Yamane K, Jinnin M, Etoh T, et al. Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med (Berl). 2013;91(1):69–81. DOI:https://doi.org/10.1007/s00109-012-0935-7.
- Danczak-Pazdrowska A, Pazdrowski J, Polańska A, et al. Profiling of microRNAs in actinic keratosis and cutaneous squamous cell carcinoma patients. Arch Dermatol Res. 2021. DOI:https://doi.org/10.1007/s00403-021-02221-2.
- Choi JG. 1095P exosomal microRNA in serum is a prognostic factor in cutaneous squamous cell carcinoma. Ann Oncol. 2020.
- Bresler SC, Padwa BL, Granter SR. Nevoid basal cell carcinoma syndrome (gorlin syndrome). Head Neck Pathol. 2016;10(2):119–124.
- Mayer JE, Goldman RH. Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water. Int J Dermatol. 2016;55(11):e585–e591.
- Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303–317. DOI:https://doi.org/10.1016/j.jaad.2018.03.060.
- Wozniak-Rito A, Zalaudek I, Rudnicka L. Dermoscopy of basal cell carcinoma. Clin Exp Dermatol. 2018;43(3):241–247.
- Dika E, et al. Basal cell carcinoma: A comprehensive review. Int J Mol Sci. 2020;21(15):5572. DOI:https://doi.org/10.3390/ijms21155572.
- Kim DP, Kus KJB, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin North Am. 2019;33(1):13–24.
- Frampton JE, Basset-seguin N. Vismodegib: A review in advanced basal cell carcinoma. Drugs. 2018;78(11):1145–1156.
- Hu P, Ma L, Wu Z, et al. Expression of miR-34a in basal cell carcinoma patients and its relationship with prognosis. J BUON. 2019;24(3):1283–1288.
- Corapli M, Pehlivanoglu B, Bulut HT, et al. Merkel cell carcinoma of the gluteal region: a rare case report and literature review. J Pak Med Assoc. 2021;71(4):1273–1276. DOI:https://doi.org/10.47391/JPMA.957.
- Navarrete-Dechent C, Cordova M, Aleissa S, et al. Dermoscopy and reflectance confocal microscopy of intraepidermal Merkel cell carcinoma. Australas J Dermatol. 2021;62(2):238–241. DOI:https://doi.org/10.1111/ajd.13513.
- Turkkan G, Agdogan O, Saynak M, et al. Recurrent Merkel cell carcinoma of the gluteal region: a case report. Dermatol Ther. 2019;32(1):e12749. DOI:https://doi.org/10.1111/dth.12749.
- Coggshall K, Tello TL, North JP, et al. Merkel cell carcinoma: An update and review: Pathogenesis, diagnosis, and staging. J Am Acad Dermatol. 2018;78(3):433–442. DOI:https://doi.org/10.1016/j.jaad.2017.12.001.
- Cornejo C, Miller CJ. Merkel cell carcinoma: updates on staging and management. Dermatol Clin. 2019;37(3):269–277.
- Garcia-Gil MF, Ramirez-Lluch M, Concellon-Donate MA. RF immunotherapy in Merkel cell carcinoma. Actas Dermosifiliogr. 2021;112(6):553–555.
- Hughes MP, et al. Merkel Cell Carcinoma: epidemiology, Target, and Therapy. Curr Dermatol Rep. 2014;3:46–53.
- Fan K, Ritter C, Nghiem P, et al. Circulating cell-free mir-375 as surrogate marker of tumor burden in Merkel cell carcinoma. Clin Cancer Res. 2018;24(23):5873–5882. DOI:https://doi.org/10.1158/1078-0432.CCR-18-1184.
- Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–10518. DOI:https://doi.org/10.1073/pnas.0804549105.
- Asangani IA, Rasheed SAK, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128–2136. DOI:https://doi.org/10.1038/sj.onc.1210856.
- Medimegh I, Omrane I, Privat M, et al. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: Interaction with clinical outcome. PLoS One. 2014;9(11):e111877. DOI:https://doi.org/10.1371/journal.pone.0111877.
- Mei M, Ren Y, Zhou X, et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat. 2010;9(1):77–86. DOI:https://doi.org/10.1177/153303461000900109.
- Peng Q, Zhang X, Min M, et al. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(27):44893–44909. DOI:https://doi.org/10.18632/oncotarget.16488.
- Qu K, Lin T, Pang Q, et al. Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations. Oncotarget. 2016;7(23):33994–34010. DOI:https://doi.org/10.18632/oncotarget.9188.
- Zhao W, Zhao -J-J, Zhang L, et al. Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int J Clin Exp Med. 2015;8(9):14759–14763.
- Leidinger P, Galata V, Backes C, et al., Longitudinal study on circulating miRNAs in patients after lung cancer resection. Oncotarget. 6(18): 16674–16685. 2015. DOI:https://doi.org/10.18632/oncotarget.4322